• Filter by age:
  • all adults (15-64) |
  • young adults (15–34) |
  • youngest adults (15–24)
• Filter by gender:
  • females |
  • males
• Filter by prevalence:
  • last 30 days |
  • lifetime |
  • last 12 months
• Filter by drug type:
  • amphetamines |
  • cannabis |
  • cocaine |
  • ecstasy

Statistics found where the type is figure and where the category is General population surveys of drug use (GPS)

Category	Title	Type
GPS	Figure GPS-1. Last 12 months prevalence of cannabis use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15- to 24-year-old age group, measured by national population surveys	figure
GPS	Figure GPS-2. Continuation rates of cannabis use (last 12 months and last 30 days use among lifetime users) in the general population, as measured by national surveys	figure
GPS	Figure GPS-3. Last 30 days prevalence of cannabis use among the 15-to 24-year old age group, measured by national surveys	figure
GPS	Figure GPS-4. Trends in last 12 months prevalence of cannabis use among young adults (aged 15 to 34), measured by national surveys Part (i) All countries	figure
GPS	Figure GPS-4. Trends in last 12 months prevalence of cannabis use among young adults (aged 15 to 34), measured by national surveys Part (ii) Countries with three or more surveys	figure
GPS	Figure GPS-5. Last 12 months prevalence of amphetamines use among young adults aged 15 to 34 and 15 to 24, measured by population surveys	figure
GPS	Figure GPS-6. Last 12 months prevalence of amphetamines use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries	figure
GPS	Figure GPS-7. Last 30 days prevalence of cannabis use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group	figure
GPS	Figure GPS-8. Trends in last 12 months use of amphetamines among young adults (aged 15 to 34), measured by population surveys Part (i) All countries	figure
GPS	Figure GPS-8. Trends in last 12 months use of amphetamines among young adults (aged 15 to 34), measured by population surveys Part (ii) Countries with three or more surveys	figure
GPS	Figure GPS-9. Last 12 months prevalence of ecstasy use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24-year-old age group Part (i) All Member States with available information	figure
GPS	Figure GPS-9. Last 12 months prevalence of ecstasy use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24-year-old age group Part (ii) Males 15 to 24 in Member States with higher prevalence rates	figure
GPS	Figure GPS-10. Last 12 months prevalence of cannabis use by age group in United Kingdom (E&W), measured by national population surveys	figure
GPS	Figure GPS-11. Continuation rates of ecstasy (last 12 months and last 30 days use among lifetime users) in the general population, as measured by national surveys	figure
GPS	Figure GPS-12. Last 12 months prevalence of cannabis use by age group in some Member States, measured by national population surveys — last survey available Part (i) Last 12 months prevalence in some of the EU-15 Member States	figure
GPS	Figure GPS-12. Last 12 months prevalence of cannabis use by age group in some Member States, measured by national population surveys — last survey available Part (ii) Last 12 months prevalence in some ‘new’ EU Member States	figure
GPS	Figure GPS-13. Last 12 months prevalence of cocaine use among all young adults (aged 15 to 34) by gender, measured by national surveys	figure
GPS	Figure GPS-14. Trends in last 12 months prevalence of cocaine use among young adults (aged 15 to 34), measured by population surveys Part (i) All countries	figure
GPS	Figure GPS-14. Trends in last 12 months prevalence of cocaine use among young adults (aged 15 to 34), measured by population surveys Part (ii) Countries with three or more surveys	figure
GPS	Figure GPS-15. Last 12 months prevalence of cocaine use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries	figure
GPS	Figure GPS-16. Continuation rates of cocaine use (last 12 months and last 30 days use among lifetime users) in the general population, measured by national surveys	figure
GPS	Figure GPS-17. Last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34)	figure
GPS	Figure GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34) Part (i) Cannabis use — lifetime experience, last 12 months and last 30 days prevalence	figure
GPS	Figure GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34) Part (ii) Cocaine, amphetamines and ecstasy use — lifetime experience, last 12 months and last 30 days prevalence	figure
GPS	Figure GPS-20. Lifetime and last 12 months prevalence of cocaine use among young adults (aged 15 to 34) in Europe, Canada, Australia and the USA — last survey available for each country	figure
GPS	Figure GPS-21. Trends in last 12 months prevalence of ecstasy use among young adults (aged 15 to 34), measured by population surveys Part (i) All countries	figure
GPS	Figure GPS-21. Trends in last 12 months prevalence of ecstasy use among young adults (aged 15 to 34), measured by population surveys Part (ii) Countries with three or more surveys	figure
GPS	Figure GPS-22. Continuation rates of amphetamines use (last 12 months and last 30 days use among lifetime users) in the general population, as measured by national surveys	figure
GPS	Figure GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34) in some Member States Part (i) United Kingdom (E&W)	figure
GPS	Figure GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34) in some Member States Part (ii) Denmark	figure
GPS	Figure GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34) in some Member States Part (iii) Germany	figure
GPS	Figure GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34) in some Member States Part (iv) Spain	figure
GPS	Figure GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (v) France	figure